Clinical trials: Brain Hemorrhage
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Head Injury
Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury
The purpose of this study is to demonstrate proof of clinical concept that application of the Intrathoracic Pressure Regulator (ITPR) will result in an increase in Cerebral Perfusion Pressure (CPP) and a decrease in Intracranial…
- Trial name
- NCT01824589
- Testing
- -7 cm H2O ITPR, -12cm H2O ITPR
- Volunteers
- 1 people
- Sponsor
- Advanced Circulatory Systems
Hemorrhagic Stroke
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion.
- Trial name
- ETHICHS (NCT03743103)
- Testing
- Brevibloc, 10 Mg/mL Intravenous Solution, Nitroprusside, Sodium
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Acquired Bleeding Disorder, Trauma
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
- Trial name
- NCT00124293
- Testing
- activated recombinant human factor VII
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
TBI (Traumatic Brain Injury)
A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection
The purposes of this study are: 1. To determine the sensitivity and specificity of the Near-Infrared Spectroscopy (NIRS) measurements for identifying intracranial hematomas due to trauma. 2.
- Trial name
- NCT00576147
- Testing
- Infrascanner
- Where
- 4 sites in United States
- Volunteers
- 431 people
- Sponsor
- InfraScan, Inc.
Intracerebral Hemorrhage
ADVANCE- Automated Detection and Volumetric Assessment of ICH
To evaluate the performance of the Viz ICH VOLUME algorithm.
- Trial name
- NCT04733638
- Testing
- Viz ICH VOLUME
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viz.ai, Inc.
Intracerebral Hematoma
Stereotactic, Robot-assisted Intracerebral Hemorrhage Clot Evacuation
Non-traumatic intracerebral hemorrhage (ICH) affects approximately 100,000 Americans yearly. Up to 30-50% of ICH is fatal, and those patients who survive are often left with significant neurologic dysfunction.
- Trial name
- NCT03414307
- Testing
- Intracerebral catheter placement, Robot-assisted intracerebral catheter
- Where
- United States
- Sponsor
- Zimmer Biomet
Intracerebral Hemorrhage (ICH)
GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage
The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.
- Trial name
- NCT01298830
- Testing
- GLP-1 CellBeads
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
InTracranial Haemorrhage
FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage
FAITH study is a multicentre retrospective analysis study that aims to understand the burden of ICH related to FXa inhibitors and the current treatment approaches in country/countries where specific reversal agents are not…
- Trial name
- FAITH (NCT06420011)
- Where
- 10 sites in Argentina, Brazil and 5 more
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI)
Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)
This study will be targeting patients suffering from acute brain injury (ABI), including those with severe trauma brain injury (sTBI) and those with aneurysmal sub arachnoid hemorrhage (aSAH).
- Conditions
- Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI), Subarachnoid Hemorrhage, Aneurysmal
- Trial name
- MCTs and ABI (NCT02716532)
- Testing
- Peptamen AF
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Société des Produits Nestlé (SPN)
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Secondary Prevention, Stroke
Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
To investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (ASA) in clinical practice
- Conditions
- Secondary Prevention, Stroke, Ischemic Heart Disease, Coronary Heart Disease
- Trial name
- EPISAT (NCT02550717)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465), Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
- Where
- United Kingdom
- Volunteers
- 398,158 people
- Sponsor
- Bayer
Cerebral Hemorrhage, Intraventricular Hemorrhage
Active Removal of IntraCerebral Hematoma Via Active Irrigation
Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.
- Trial name
- ARCH (NCT05118997)
- Testing
- IRRAflow, EVD
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- IRRAS
Intracerebral Hemorrhage
AI ENRICH - AI Detection of ICH
To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.
- Trial name
- NCT03865979
- Testing
- Viz RECRUIT
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Viz.ai, Inc.
Atrial Fibrillation, Stroke
CHAMPION-AF Clinical Trial
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- CHAMPION-AF (NCT04394546)
- Testing
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Where
- 141 sites in United States, Australia and 14 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Thrombosis, Stent Thrombosis
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of…
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction
- Trial name
- CARES2 (NCT04702113)
- Testing
- Cipherome Lighthouse Pilot
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cipherome, Inc.
Aneurysmal Subarachnoid Hemorrhage
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain due to the presence of blood in the space…
- Trial name
- REVERSE (NCT02560532)
- Testing
- Clazosentan
- Where
- 11 sites in Finland, France and 1 more
- Volunteers
- 25 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Subarachnoid Hemorrhage, Optical Imaging
A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury
To assess the feasibility of a new neuromonitoring system (NeMoSystem including NeMo Probe and NeMo Patch) and the accuracy of the measurement values (cerebral blood flow (CBF); cerebral blood volume (CBV)) obtained.
- Trial name
- NCT01802762
- Testing
- NeMo Patch and NeMo Probe
- Where
- 2 sites in Austria, Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- NeMoDevices AG
Traumatic Subdural Hematoma
Factors Influencing Readmission Rates of Acute Traumatic Subdural Hematoma in the Elderly
Acute traumatic subdural hematomas (TSDH) readmission rate is high (27.8%) with an increase in morbidity and cost for the elderly.
- Trial name
- NCT03878043
- Testing
- Follow-up Care
- Where
- United States
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Tarik Wasfie, MD